We also emphasise a translational viewpoint that goes beyond descriptive summaries by proposing how targeting upstream signalling hubs that modulate the Bcl-2:beclin-1 axis may sensitise GBM cells to death pathways, supported by experimental and preclinical evidence. This evidence concerns the gene BECN1 and glioblastoma.